Cogent Biosciences plans to submit an NDA to the FDA, with Andrew Robbins as President and CEO.
1 report, 0 independent
Updated Jul 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cogent Biosciences plans to submit an NDA to the FDA, with Andrew Robbins as President and CEO.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- FDA acceptance of NDA supports drug development.Sub-event
- Cogent Biosciences plans NDA submission to FDA.
Keep exploring
The entities involved
- FDA
-
Cogent Biosciences (United States)
company in Waltham, United States
Nothing else this week.
Related events
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Cuong Do leads BioVie as its CEO. BioVie Inc is listed on the NASDAQ exchange and is seeking FDA review for its drug candidate.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- The FDA and the Securities and Exchange Commission entered into a Memorandum of Understanding (MOU) to enhance cooperation between the two agencies.
Coverage
Newest first; wire copies grouped- Unknown outlet